Form 4: Edwards Lifesciences Insider Trades Common Stock

Daniel J. Lippis of Edwards Lifesciences Corp. reported transactions involving common stock and employee stock options on July 10, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Daniel J. Lippis, Chief Administrative Officer and Corporate Vice President at Edwards Lifesciences Corp., reported transactions on July 10, 2026.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on February 13, 2026.
• Lippis acquired 619 shares of common stock at a price of $72.68 per share.
• Lippis also disposed of 619 shares of common stock at a price of $91.70 per share.
• Following these transactions, Lippis beneficially owns 40,652.9103 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports routine insider transactions executed under a pre-defined plan, without indicating significant positive or negative developments for the company.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-impactful trading activity.
• The acquisition of shares at a lower price ($72.68) and disposal at a higher price ($91.70) suggests a potentially profitable execution within the plan.
• The reporting person continues to hold a significant number of shares (40,652.9103) after the reported transactions.

Negatives

• The disposal of shares, even under a plan, represents a reduction in the reporting person's direct holdings.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a senior executive like Daniel J. Lippis (CVP, TAVR) at Edwards Lifesciences (EW) is common practice to manage personal stock sales and purchases in a way that can provide an affirmative defense against allegations of insider trading.

Stakeholder Impact

• Shareholders: The transactions are part of a pre-arranged plan and do not necessarily indicate a change in management's outlook on the company's performance. The continued beneficial ownership by the reporting person may be viewed positively.
• Employees: No direct impact is indicated for employees.
• Creditors: No direct impact is indicated for creditors.
• Suppliers: No direct impact is indicated for suppliers.
• Customers: No direct impact is indicated for customers.

Key Dates

Keywords

Form 4, Insider Trading, Edwards Lifesciences, EW, Common Stock, Rule 10b5-1, Stock Options, Beneficial Ownership, SEC Filing